The recombinant collagen technology was developed by USC dermatology professors Mei Chen and David Woodley.
The license includes their work in dystrophic epidermolysis bullosa (DEB), an orphan disease that causes skin blisters, morbidity and early mortality, as well as their rC7 research in accelerated chronic wound healing and bone repair indications.
Lotus Tissue Repair is advancing the licensed rC7 technology as a protein replacement therapy for the treatment of DEB.
Future applications of the technology include treatments for dermatologic conditions in which rC7 plays a role in accelerating chronic wound healing, such as diabetic foot ulcers, venous stasis ulcers and similar conditions.
Lotus CEO Mark de Souza said they look forward to work closely with them as scientific founders of the company to advance this program and to explore broader applications of the rC7 technology for chronic wound healing.
